HOME >> MEDICINE >> NEWS
NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

dicine and director of the AIDS unit; Dr. David Wohl, research fellow in medicine; and research clinician Janet Groves.

Nationwide, researchers found 63 "disease progression events" -- including AIDS-related illnesses and deaths among patients receiving a combination of ZDV and 3TC, Eron said. Among patients receiving those two drugs and indinavir, they found only 33 such events.

"There were 18 deaths in the double-therapy arm of the study vs. eight deaths in the triple- therapy arm," he said. "No major differences were found in either safety or toxicity between the two treatments, and study medications were well-tolerated."

Indinavir, a protease inhibitor, works by preventing protease enzymes from cutting up proteins needed to form viruses, Eron explained. The envelope, or outer coating, of the virus still develops, but the core cannot, and therefore the resulting virus is not infectious.

Drugs such as ZDV and 3TC work by inhibiting an enzyme called reverse transcriptase. That enzyme enables the virus' genetic material, or RNA, to convert human genetic material known as DNA into more virus.

The Food and Drug Administration approved use of the combined ZDV and 3TC in November 1995, in part because of a national study Eron led and published in the New England Journal of Medicine. Indinavir has been approved for about a year.

"The people who should be thanked and congratulated for this study and others like it are the people who participated in the trials," Eron said. "They not only have done something that will improve their own care, but they have volunteered to do something that will clearly improve the care of many patients afterwards.

"Treatment with the triple-drug therapy is not easy because of the large number of pills patients have to take and the commitment they have to make to stick to the therapy," he said. "They are the real heroes here."

Glaxo-Wellcome Inc. of Research Triangle Park
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-2091
University of North Carolina at Chapel Hill
25-Feb-1997


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill ... Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and ...
(Date:7/30/2015)... ... , ... Using the latest online digital technologies, happiness expert Kay Walker is ... and manage major depression. , “Suicide is 100% preventable. The problem is the medical ... and die needlessly everyday,” says Walker. “I’m out to end suicide. Some may say ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web ... annual All-Stars Summit. Google Partners is the platform for search marketing agencies to ... support and tools necessary to run successful search marketing campaigns. Google Partners also ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV infection rates ... Florida on June 17th. Those untreated heroin use disorders share their needles and ... of dirty needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2
(Date:7/30/2015)... BURLINGAME, Calif. , July 30, 2015 /PRNewswire/ ... Patent and Trademark Office has granted the company ... property covering Cleave,s lead molecule CB-5083. ... quinazolines as inhibitors of p97," U.S. 9,062,026, allows ... CB-5083, a first-in-class, highly selective oral inhibitor of ...
(Date:7/30/2015)... , July 30, 2015  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... quarter fiscal year 2015 financial results after the market ... call will follow on the same day at 4:30 ... President and Chief Executive Officer, and Rick Eiswirth ...
(Date:7/30/2015)...   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the ... revenue of $73.6 million for the quarter ended ... the quarter ended June 30, 2014.  Currency fluctuations ... nine percentage points, during the three months ended ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
Cached News: